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Teaser This review presents current treatments generally used in acute myeloid leukemia
therapy, and highlights innovative formulations designed to overcome drug resistance or
adverse effects observed with current treatments.
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Acute myeloid leukemia (AML) is the most common cause of leukemia-
related mortality. The combination of cytarabine and anthracycline has
been the gold standard of treatment over the past 40 years, but the
distribution of the drugs in the body leads to severe adverse effects. Poor
prognosis of older patients with AML is the consequence not only of
comorbidities, but also of chemoresistance resulting from frequent
secondary AML. Numerous strategies using nanotechnologies are in
development to improve drug targeting, pharmacokinetics,
administration route, chemoresistance, and adverse effects generally
observed. Among the four new drugs approved for AML by the US Food and
Drug Administration (FDA) in 2017, Vyxeos1 is a novel liposomal
formulation of historical AML drugs. Here, we review current AML
treatments and discuss how the development of new formulations will
change the therapeutic armamentarium.
Introduction
AML is the most common acute leukemia in adults, and its incidence increases with age.
Although the disease is usually of unknown etiology, it can develop following either an
underlying hematological disorder (e.g., myelodysplastic syndromes, MDS) or exposure to
genotoxic agents (e.g., topoisomerases II, alkylating agents, or radiation). The pathogenesis of
AML involves successive genomic alterations in multipotential hematopoietic stem cells and
leads to the abnormal clonal proliferation and differentiation of myeloid cells.
AML mainly affects adult patients, with a median age of 64 years [1]. Prognosis remains poor,
especially in older patients, with fewer than 30% of patients surviving within a year of diagnosis [2].
Although our understanding of the disease as well as its biological characteristics has advanced
in recent decades, induction therapy has changed little since 1973. However, the therapeutic
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drugs approved by the FDA. Among them, Vyxeos1 (Jazz Phar-
maceuticals) is a novel liposomal formulation of a co-encapsula-
tion of daunorubicin and cytarabine.
The principal adverse effect generally observed in AML treat-
ment is myelosuppression with neutropenia, which can lead to
severe infections, anemias requiring red blood cell transfusions,
and thrombocytopenia involving hemorrhagic events. Support-
ive care with anti-infectious treatments, such as antifungals,
antibiotics, and antivirals [3,4] and growth factors [5] has led
to improved overall survival rates for patients with AML over
recent decades [6,7].
Here, we highlight innovative formulations as a potential way
to optimize AML chemotherapies. Specifically, we focus on how
nanoparticles (NPs) might be designed to counteract adverse
effects, enhance treatment compliance, avoid resistance, or pro-
long exposure to chemotherapy.
Current treatments
In younger patients, AML requires the instauration of therapy with
a minimal delay after diagnosis [8]. By contrast, delaying AML
treatment does not affect prognosis in older patients, except those
with very proliferative disease [9]. Intensive chemotherapy is the
gold standard for younger patients with AML, whereas epigenetic
therapy is an option for older patients, especially those with
comorbidities or belonging to high-risk populations (i.e., second-
ary AML or poor risk cytogenetics) [10].
Standard chemotherapy
Induction therapy for younger patients with AML in 2018
remains largely as it was during the 1970s [11]. The most
common therapy used in AML is the ‘7 + 3 regimen’, a combi-
nation of cytarabine (a nucleoside analog) combined with dau-
norubicin or idarubicin (an anthracycline) [12]. Patients eligible
for intensive chemotherapy usually undergo this treatment,
which comprises a continuous infusion of cytarabine (100–
200 mg/m2) for 7 consecutive days and daunorubicin at
60 mg/m2 or idarubicin at 12 mg/m2 on Days 1–3. Reducing
daunorubicin to 45 mg/m2 per day is considered suboptimal
[13], whereas it is thought that idarubicin is associated with a
higher cure rate in the long term [14]. After induction, complete
remission is achieved in 60–80% of younger patients with AML,
compared with approximately 45–65% in older patients
[13,15,16]. This induction is then followed by consolidation
therapy during the postremission phase. This therapy comprises
two to four cycles of high-dose cytarabine (2000–3000 mg/m2/
day given on Days 1, 3, and 5) and can be followed by hemato-
poietic stem cell transplantation depending on age, AML risk
group, and donor availability.
Specific therapy
The introduction of all-trans retinoic acid (ATRA) into the thera-
py of acute promyelocytic leukemia (APL), which represents 10–
15% of all cases of AML, completely revolutionized the manage-
ment and outcomes of this disease [17]. ATRA combined with
anthracyclines results in a remission rate of >90%, and provides
the first example of molecularly targeted treatment in AML [18].
ATRA, administered orally at 45 mg/m2 twice daily, is presentedPlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute m
2 www.drugdiscoverytoday.comas 10-mg soft capsules in which ATRA is solubilized in a mixture
of yellow beeswax, hydrogenated soya bean oil, partially hydro-
genated soya bean oil, and soya bean oil. ATRA has also been
combined with arsenic trioxide (ATO), as a result of synergy in
inducing differentiation and apoptosis. The combination of
ATRA with ATO resulted in the first chemotherapy-free regimen
for AML and has become the new standard for APL [19] with
inferior toxicity compared with ATRA combined with chemo-
therapy [20,21].
Relevant molecular targets have been discovered in AML. For
example, isocitrate dehydrogenases (IDHs) can be mutated, lead-
ing to the accumulation of R-2-hydroxyglutarate in the cell.
Mutations of two isoforms of IDHs (IDH1 and IDH2) have been
linked to epigenetic changes resulting in global dysregulation of
gene expression. Those mutations have been found in approxi-
mately 20% of patients with newly diagnosed AML [22]. FMS-like
tyrosine kinase 3 (FLT3) is a gene that encodes a tyrosine-kinase
and is mutated in some patients with AML. Mutant forms of FLT3
can be targeted by kinase inhibitors [23].
Midostaurin was the first kinase inhibitor approved for AML by
the FDA and the European Medicines Agency (EMA), in 2017. This
drug is given orally at 50 mg twice daily in association with the
conventional ‘7 + 3 regimen’, in AML with FLT3 internal tandem
duplication or tyrosine kinase activation. In the RATIFY trial, the
median overall survival was prolonged from 25.6 to 74.7 months
with midostaurin in patients aged 18–59 years [24].
The FDA also provided accelerated approval for the oral IDH2
inhibitor enasidenib in August 2017, based on a promising Phase
2 study in relapsed or refractory AML [25]. Given orally at 100 mg
per day, alone, this treatment produced an overall response rate
of 37%. Based on these results, this treatment is likely to be
combined in the near future with conventional chemotherapy
or demethylating agents in patients with first-line AML and IDH2
mutations.
Other targeted agents inducing mutations are under develop-
ment, such as IDH1 inhibitors (ivosidenib) [26] and BCL2 antago-
nism (venetoclax) either alone or in combination [27–29].
Interesting reviews of new active pharmaceutical ingredients
(API) used in AML treatment are available elsewhere [30,31].
Antibody–drug conjugates
Gemtuzumab ozogamicin (GO) was the first antibody-drug con-
jugate approved by the FDA for CD33-positive AML. CD33 is a
membrane receptor expressed by myeloid progenitors but not
present in normal hematopoietic stem cells. This drug is a hu-
manized anti-CD33 antibody conjugated to calicheamicin (a
DNA-intercalating antibiotic). Accelerated approval was given
by FDA in 2000 but withdrawn 10 years later because of increased
treatment-related mortality [32]. Final approval was given in
2017 based on new GO dose regimens [33]. In addition to new
CD33-targeting agents, other clinical trials targeting CD123 are
ongoing [34].
Epigenetic therapy
For patients who are not candidates for intensive chemotherapy,
such as older patients with comorbidities or relapsed or refractory
AML, lower intensity therapy is required. For several years, the
only solutions available were best-supportive care or low-doseyeloid leukemia, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.05.040
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sented by hypomethylating agents, such as decitabine (DEC)
and azacytidine (AZA). The role of epigenetic deregulation in
the pathogenesis of AML and MDS has been a focus of intense
research over the past 10 years. Initially developed for patients
with higher-risk MDS, DEC and AZA have shown their ability to
improve median overall survival compared with low-dose cytar-
abine or supportive care only [35,36]. In AML, both hypomethy-
lating agents have been compared with conventional care
regimens in two Phase 3 trials [10,37], in which they displayed
an improvement in median overall survival rates as well as lower
toxicity. Whereas DEC injected intravenously at 20 mg/m2 every
day over 5 days, repeated every 4 weeks, was approved in 2012 by
the EMA for older patients with de novo AML who were not
candidates for standard induction therapy [38], it is only approved
by the FDA for patients with MDS. AZA (75 mg/m2) subcutane-
ously for 7 days every 28 days is also approved in the USA and
Europe for MDS, but not for AML. However, patients with 20–30%
bone marrow blasts (refractory anemia with excess blast in trans-
formation according to French-American-British subtypes) are
now considered patients with AML according to the WHO’s clas-
sification [39], meaning that the use of DEC and AZA is a labeled
option.
Other novel agents currently under investigation in clinical
trials were recently reviewed by Montalban et al. [40].
Questions and challenges for AML treatment
Chemotherapies used in AML are mostly presented as solutions
and are administered intravenously. A general distribution is
mostly observed without drug targeting towards specific cells.
Therefore, these chemotherapies can lead to general adverse
effects, such as pancytopenia or cardiac toxicities related to
anthracyclines. Treatment-related mortality is high, especially
in the older population. However, specific AML therapies are
mostly oral treatments, although the new schedules developed
for patients with AML are also affected by adverse effects and drug
resistance. Tyrosine kinase inhibitors are associated with digestive
adverse effects (vomiting, nausea, diarrhea, and heartburn), vari-
ous types of skin rash, headaches, muscle cramps, heart dysfunc-
tion, hepatic impairments, pulmonary toxicities, or
cardiotoxicities [40–42].
Despite new treatments, personalized therapies and many clin-
ical trials, overall survival remains poor. Complete remission is
reached in 70–80% of younger patients with AML (<60 years),
compared with only 45–65% of older patients with AML because of
comorbidities and drug resistance [13,43]. Moreover, according to
European Leukemia Net, median overall survival falls from 15.5 to
5.5 years in favorable AML genetic groups among patients over the
age of 60 [44]. Relapse occurs when drugs are unable to eradicate
leukemic stem cells (LSCs) protected in the hematopoietic niche.
One of the major causes of drug resistance is the altered function of
transmembrane transporters. Several members of the ATP-binding
cassette transporters family are upregulated in tumor cells [45],
and could be a target in AML [46].
To bypass these phenomena, pharmaceutical technologies,
such as nanotechnologies, are being developed, and this field
represents a promising approach [47]. In particular, in AML thera-
py, nanocarriers could prolong the half-life of drugs generallyPlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute madministered via an intravenous administration, thus enhancing
the contact of the drug with cells. Specific cells, such as LSCs, could
be targeted to reduce relapses [48,49]. Finally, modifying the
administration route can help to improve patient compliance,
especially of older patients.
Challenges for innovative formulations
According to the definition given by the FDA and the EMA,
nanomaterials involved in drug delivery should have at least
one external, internal, or surface structure in the nanoscale range
(1–100 nm). Nanomaterials involved in drug development can
include liposomes, lipid NPs, polymeric NPs, micelles, dendrimers,
and metallic NPs, depending on their formulation process and
their composition. Since the first nanocarriers were developed,
several approaches have emerged to enhance their effectiveness,
depending on the purpose of the nanocarrier. Typically, four
generations of NPs have been distinguished over time. In the first
one, particles were ‘nude’ and rapid opsonizations were observed.
In the second generation, hydrophilic polymers were grafted onto
the surfaces of NPs to form a brush-like barrier. Slowed protein
adsorption onto NPs was achieved, and mean blood residence
times were enhanced. Second-generation particles diffuse to solid
tumors because of the enhanced permeability and retention (EPR)
effect. However, this effect does not appear to work in human
therapeutics [50] and has no implications for therapeutics in AML,
a nonsolid tumor cancer. Third-generation particles comprise NPs
with specific ligands on their surfaces, designed specifically to
target cells of interest. The fourth generation corresponds to
theranostic strategies (multifunctional nanocarriers that combine
a diagnostic agent with a therapeutic agent) or targeting cell
organelles [51].
Several nanocarrier formulations have been approved and are
available on the US, European, Indian, Japanese, or Chinese mar-
kets. They are mostly liposomal formulations and are largely used
for solid tumors. Nanocarriers are generally designed for four main
reasons: (i) drug targeting with the aim of reducing adverse effects
resulting from the general distribution of the API or from exci-
pients; modify drug pharmacokinetics; (3) bypass drug resistance;
and (4) modify the route by which the drug is administered or to
improve the oral bioavailability of APIs [52]. This can lead to
improved quality of life for patient if intravenous administration
is replaced by oral administration.
Other hematologic malignancies have also been treated using
liposomal formulations. For example, liposomal pegylated doxo-
rubicin formulations, indicated in multiple myeloma, decrease the
cardiac toxicity associated with anthracycline. However, new
adverse effects have been observed with these formulations, such
as acute hypersensitivity reactions. Liposomal formulations modi-
fy doxorubicin pharmacokinetics by increasing its half-life and
plasma concentration (area under curve increased) and decreasing
the volume of distribution [53]. Moreover, doxorubicin-loaded
liposomes are less subject than free doxorubicin to multidrug
resistance mechanisms driven by p-glycoprotein, and are capable
of reversing multidrug resistance efflux mechanisms [54].
There are a few NP formulations on the market, and one,
Vyxeos1, was approved for AML treatment by the FDA in 2017.
This liposomal formulation is a co-encapsulation of cytarabine
and daunorubicin, and is discussed in more detail below.yeloid leukemia, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.05.040
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Chemotherapeutic drug-loaded nanocarriers involved in clinical trials in December 2017 in an AML indicationa
Nanocarrier category Drug Clinical trial phase Clinical trial ID
Polymeric NPs AZD2811 1–2 NCT03217838
Liposomes Vincristine 1 NCT00933985
2 NCT02337478
Cytarabine–daunorubicin Not provided NCT01804101
1 NCT00875693
1–2 NCT02642965
2 NCT02286726/NCT00822094/NCT02019069/
NCT00788892/NCT02269579/NCT02238925/NCT03335267
3 NCT01696084
Grb2 antisense oligonucleotide 1 NCT01159028
2 NCT02781883
Doxorubicin 1 NCT00003243
1–2 NCT00237627
3 NCT01736943
Annamycin 1 NCT00430443
1–2 NCT03315039
Daunorubicin 1 NCT02722135
1–2 NCT00005942
2 NCT00005962
2–3 NCT00111345
3 NCT02724163/NCT00186966
Cytarabine 1 NCT00003073
2 NCT00002547
a From clinicaltrials.gov, December 2017.
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search terms ‘acute myeloid leukemia’ and ‘liposomes’,
‘nanoparticles’, ‘nanocarriers’, ‘micelles’ or ‘nanocapsules’ were
found on the clinicaltrials.gov website in December 2017 (Table 1).
Among the 42 clinical trials, eight corresponded to antifungal
drugs, and six did not used nanocarrier formulations but were
found because of their use of associated keywords (MESH terms).
Finally; 28 clinical trials were identified that used liposomal for-
mulations; but only one was based on polymeric NPs. No other NP
formulation is currently under clinical investigation for the treat-
ment of AML.
Innovative nanocarrier formulations
Liposomes
Liposomes are vesicles generally comprising phospholipids and
cholesterol in a bilayer arrangement (Fig. 1). Liposomes can be
loaded with one or more molecules in the aqueous compartment
or in the lipidic bilayer. Liposomal formulations are already used
in clinical settings for non-AML indications, such as anti-infec-
tious drug encapsulation (amphotericin B, Ambisome1, Astellas
Pharma), analgesic drugs [morphine sulfate, Depodur1, Pacira
Pharmaceuticals (commercialization discontinued)] or cytotoxic
drugs. In terms of cytotoxic drugs, only two drug classes have been
encapsulated into liposomes; anthracycline and antimetabolite
agents. Two anthracycline molecules were encapsulated and
reached the market, namely doxorubicin (Caelyx1, Janssen-Cilag
International N.V, Doxil1, Janssen-Cilag International N.V, and
Myocet1, Teva B.V.) and daunorubicin (Daunoxome1, Gilead
Sciences) for which commercialization was discontinued. Cytar-
abine (DepoCyt1, Pacira Ltd) is the only representative drug of the
antimetabolite class encapsulated in a liposome-like structure
(nonconcentric vesicles). The commercialization of Depocyt1
was discontinued in 2017. The main advantages of liposomesPlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute m
4 www.drugdiscoverytoday.comare that they have shown a good ability for large-scale production
(i.e., the presence of drug products on the market) and also their
tolerance is now well studied.
Liposomes approved as AML therapy
In 2017, the FDA approved Vyxeos1 (previously denoted CPX-
351), a liposomal formulation with a co-encapsulation of cytar-
abine and daunorubicin in a 5:1 molar ratio. To obtain theses
liposomes, an emulsion was formed comprising distearoylpho-
sphatidylglycerol, distearoylphosphatidylcholine, and cholester-
ol, solubilized in chloroform and dispersed in a solution
comprising copper gluconate and triethanolamine. The solvent
(chloroform) is evaporated and the film is then rehydrated and the
liposomes extruded on a polycarbonate filter [55]. Vyxeos1 is
presented in a lyophilized form and should be reconstituted with
water for injection; it should then be diluted in 0.9% sodium
chloride injection or 5% dextrose injection before intravenous
injection. The mean size of liposomes is 107 nm, with a polydis-
persity index (PI) of 0.243 and a negative surface charge (potential
zeta of 33 mV) [55]. In a Phase 2 randomized trial, CPX-351 was
compared with a ‘7 + 3 regimen’ in older patients with first-line
AML [56]. This clinical trial enrolled 127 patients, of whom 86
were allocated to the CPX-351 arm and 41 to the gold standard
treatment arm. Two courses of induction and consolidation were
allowed in each arm. CPX-351 was associated with a higher
complete remission rate and a lower 30-day treatment-related
mortality rate (3.5% versus 7.3%). It was demonstrated that lipo-
somes can enter leukemic cells intact, and this mechanism was
suggested as a means of overcoming drug resistance [57]. Indeed,
anthracyclines are susceptible to efflux pump (because of the p-
glycoprotein) and, once encapsulated into liposomes, cellular
internalization is mediated by liposome properties rather than
by anthracycline properties. Thus, daunorubicin was able to es-
cape to the p-glycoprotein. Cytarabine is rapidly metabolized byyeloid leukemia, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.05.040
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FIGURE 1
Overview of the six main types of nanocarriers involved in acute myeloid leukemia (AML) therapy at different stages of preclinical or clinical development.
Nanocarriers are generally loaded with drugs already used in AML therapy to reduce severe adverse effects and could be functionalized with specific ligands to
enhance targeting properties. Abbreviation: API, active pharmaceutical ingredient.
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protect it from this degradation pathway. CPX-351 was also eval-
uated in first relapse in younger patients with AML aged 18 to 65
[58]. This Phase 2 trial was based on 2:1 randomization [i.e., CPX-
351 or an alternative chosen by the investigator and based mainly
on cytarabine (97.3%) and anthracycline (77.3%)]. As in the
previous clinical trial, a higher number of complete remissions
was observed in the CPX-351 arm, along with a lower number of
deaths after 90 days. A Phase 3 clinical trial was then conducted in
patients aged 60 to 75 with untreated high-risk or secondary AML
(NCT 01696084). This trial recruited 309 patients and confirmed
the higher complete remission rate (47.7% versus 33.3%) and
overall survival (median, 9.56 versus 5.95 months) for CPX-351
over the ‘7 + 3 regimen’ [31,59,60].
Vyxeos1 is now labeled for the treatment of adults with newly
diagnosed therapy-related AML or AML with myelodysplasia-re-
lated changes. According to cliniclatrials.gov, in December 2017,
11 clinical trials were ongoing using the liposomal formulation ofPlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute mdaunorubicin and cytarabine (Table 1), with the aim of expanding
Vyxeos1 indications.
Liposomes under clinical trial as AML therapy
Other liposomal formulations are under clinical evaluation for
AML indications (Table 1). These are drug formulations already on
the market and are used in clinical trials as drug support to
investigate other new agents, to develop new schedule strategies,
or to investigate new chemotherapeutic agent associations. Vin-
cristine-sulfate liposome, annamycin liposomes, or BP1001 (a
liposomal growth factor receptor-bound protein-2 antisense oli-
godeoxynucleotide loaded in a liposome formulation) are new
drugs that are not yet approved. They are currently at the Phase 1
and 2 evaluation stages to determine either the maximum toler-
ated dose (annamycin liposomes and BP1001) or their efficacy
(vincristine sulfate liposomes) in patients with relapsed or refrac-
tory AML.
Liposomes can be used for co-encapsulation, and Vyxeos1 is
proof that co-delivery could be more effective than a combinationyeloid leukemia, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.05.040
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is preserved throughout drug release [61]. Moreover, Vyxeos1
confirms that using nanotechnologies could overcome drug resis-
tance, such as p-glycoprotein (anthracycline), and protect drugs
from enzymatic degradation pathways, such as cytidine deami-
nase (cytarabine).
Liposomes evaluated in in vitro or in vivo models
Other liposome formulations have been developed for AML treat-
ment, and are designed to avoid adverse effects (Fig. 2). For
example, a method has been developed for the co-delivery of
safingol and C2-ceramide [62]. Safingol is a sphingolipid with
antileukemic activity, but is not used in the clinical setting because
of its poor water solubility and hemolytic properties [63]. Tan et al.
designed liposomes for safingol encapsulation. These were pre-
pared by mixing safingol, distearoylphosphatidylcholine, and
cholesterol in chloroform before evaporating the latter. The lipid
film was then rehydrated in a HEPES buffer, which was followed by
extrusion techniques on polycarbonate filters. Finally, liposomes
with a positive zeta potential were obtained. The liposomes were
able to reduce significantly the in vitro hemolytic toxicity of
safingol and safingol plasma elimination in a mouse-based model,
and to improve survival in U937-inoculated mice (histiocytic
lymphoma cells) [63]. The same authors then developed a co-
encapsulation of safingol and C2-ceramide (1:1 molar ratio), an-
other sphingolipid [62]. Given that C2-ceramide and safingol act
independently, with different cellular pathways, the authors pos-
tulated that co-encapsulation of these two sphingolipids would
enable them to act in synergistically. A liposomal formulation was
obtained after the dissolution of the lipids (safingol, C2-ceramide,
cholesterol, and distearoylphosphatidylcholine) in chloroform.
The solvent was then evaporated, and the film obtained was
rehydrated with piperazineethanesulfonic acid buffer. The lipo-
somes were then extruded on polycarbonate filters. Liposomes of
135 nm with a co-encapsulation of safingol and C2-ceramide were
obtained that were similar to liposomes containing only C2-cer-
amide (119 nm). Liposomes significantly reduced the hemolysis
properties of sphingolipids compared with free drugs. The con-
centrations required for liposomal C2-ceramide to achieve 50%
cell death were significantly higher than those for liposomal co-
encapsulation of safingol and C2-ceramide on five leukemia cell
lines (KG-1, MV-4–11, HL-60, U937, and HEL). Finally, in vivo
experiments were carried out involving intravenous inoculation
of U937 using a mouse-based model. Despite a reduction in the
drug doses administered, co-encapsulation extended the median
survival time from 24 to 37 days compared with liposomes with
C2-ceramide encapsulation alone (P < 0.005), demonstrating
once again the potential of co-encapsulation into liposomes.
Myhren et al. also developed a liposome formulation for the co-
administration of an anthracycline (daunorubicin) and a protein
synthesis inhibitor, emetine [64]. Liposomes were grafted onto the
liposome surface with polyethylene glycol (PEG) to confer stealth
properties, and folic acid was also grafted on to target AML cells.
The liposomes comprised phosphatidylcholine, cholesterol, and
distearoyl phosphatidylethanolamine or distearoyl-glycero-phos-
phoethanolamine-N-PEG5000-folate. After the lipids were solubi-
lized in chloroform, the solvent was removed, and the film
obtained was rehydrated in ammonium sulfate buffer and then
extruded. Liposomes were then loaded with drugs by applying thePlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute m
6 www.drugdiscoverytoday.comacid-precipitation concept. Finally, liposomes with a size of 121–
127 nm (depending on the folic acid grafting), and a negative
charge of approximately 10 mV were obtained. After an in vitro
study on an AML cell line (MOLM-13), the authors showed that
liposomes with a co-encapsulation were more effective than a co-
incubation of daunorubicin-loaded liposomes and emetine-loaded
liposomes. Apoptosis was enhanced by a factor of six. However,
the authors also showed that incubation of daunorubicin-loaded
liposomes followed 30 min later by incubation of emetine-loaded
liposomes was more effective than the administration of lipo-
somes containing the two drugs.
Liposomes and biopharmaceuticals
Biopharmaceuticals are currently a research focus and liposomes
could help in administering these APIs. Biotechnology is an
emerging field with great potential in cancer treatment, and
AML is affected by this development. Biotechnology encompasses
several treatment strategies, such as gene therapy, antisense oli-
gonucleotide therapy, and chimeric antigen receptor T cells,
which were recently approved for acute lymphoblastic leukemia
treatment by the FDA. Antisense oligonucleotides refer to small
interfering (si)RNA, miRNA, or short hairpin (sh)RNA. There are
few antisense oligonucleotides on the market, probably because of
a lack of stability in blood circulation, inefficient intracellular
delivery, difficulties in targeting cells or tissues, and poor affinity
with the target sequence [65]. Therefore, as part of cancer treat-
ment strategies, different NPs were designed to improve either the
stability in the blood stream or their ability to target cancer cells
[66]. Hundreds of Phase 1, 2, and 3 clinical trials for cancer
indications are ongoing [67]. However, only two clinical trials
combining liposomes and antisense oligonucleotide for AML
treatment were found on clinicaltrials.gov in December 2017
(Table 1).
BP1001 is a liposomal formulation of an antisense oligonucleo-
tide (growth factor receptor-bound protein-2) comprising dio-
leoylphosphatidylcholine, with a mean size <900 nm, and high
encapsulation efficiency (>95%) [68]. Two clinical trials are ongo-
ing. A Phase 1 trial is underway (NCT01159028) to determine the
highest safe dose for patients with Philadelphia chromosome-
positive chronic myeloid leukemia, AML, acute lymphoblastic
leukemia, and MDS (active but not recruiting patients). The Phase
2 trial (NCT02781883) is designed for patients with newly diag-
nosed AML who are not suitable for standard or high-intensity
chemotherapy regimens (currently recruiting patients). The study
is designed to assess whether the combination of BP1001 and low-
dose cytarabine is more effective than low-dose cytarabine alone.
Other formulations are under in vitro or in vivo evaluation. miR-
126 is overexpressed in LSC [69] and the cells appear to be engaged
in AML treatment resistance; thus, targeting LSCs appears to be a
promising therapeutic approach [70]. Dorrance et al. designed
lipoplex targeting LSCs, and more specifically miR-126, with the
objective to reduce quiescent LSC and leukemia growth [49]. A
negatively charged miR-126-antagonist was mixed with positively
charged polyethylamine, producing a polyplex core that was then
added to an anionic liposomal formulation, finally resulting in a
lipopolyplex. To target LSC, transferrin or CD45 antibody was
then grafted onto the surface of the lipoplex. The formulations
were tested on mice engrafted with human AML primary blasts.
The mice were treated with lipopolyplex loaded with anti-miR-126yeloid leukemia, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.05.040
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FIGURE 2
Examples of molecules loaded in innovative formulations developed to treat acute myeloid leukemia (AML) to improve pharmacokinetic parameters as well as
reducing adverse effects or modifying the administration route.
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Wor with anti-miR-scramble (SCR) as a control. After 48 h of treat-
ment, bone marrow cells were collected and transplanted into
secondary mice. Whereas a significant improvement in survival
rate of secondary recipients was observed, there was no impact for
primary recipient mice transplanted with cells harvested after an
anti-miR-126-lipopolyplex formulation compared with mice
transplanted with cells harvested after an anti-miR-SCR-lipopoly-
plex formulation. Thus, this combination of anti-miR-126 and
chemotherapy could be an effective way to target LSCs and de-
crease leukemia relapses.
Liposomes were also developed to encapsulate GTI-2040 (also
known as LOR-2040) and to target ribonucleotide reductase,
which is overexpressed in cytarabine-resistant AML cells [71].
GTI-2040, targeting the R2 ribonucleotide reductase subunit,
was evaluated in a Phase 1 clinical trial in combination with
cytarabine. R2 downregulation was observed but no complete
remission was noted, indicating that the effect of GTI-2040 needed
to be enhanced [72]. GTI-2040-loaded immunoliposomes, grafted
with an anti-CD33 to target AML cells, were designed and evalu-
ated by Li et al. [71]. These liposomes were previously formulatedPlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute musing an emulsion comprising lipids (2,3-dioleyloxy-propyl-tri-
methylammonium chloride, dioleoylphosphatidylethanolamine,
a-tocopheryl PEG-1000 succinate, and cholesterol) solubilized in
ethanol and then injected in an HEPES buffer. Mean particle size
was 93  18 nm, and the zeta potential was relatively neutral
(4.3  0.2 mV). After cytotoxicity testing on Kasumi-1 (an AML
cell line) and K562 (chronic myelogenous leukemia cell line), the
authors developed an in vivo model of a Kasumi-1 xenografted
tumor. Following daily administration of GTI-2040-loaded immu-
noliposomes for 3 days, significantly downregulated R2 expression
was observed compared with free GTI-2040. Tumor volume de-
creased by a factor of approximately two. When combined with
cytarabine treatment, the survival of mice was also prolonged with
the use of GTI-2040-loaded immunoliposomes compared with
cytarabine alone, cytarabine plus free GTI-2040, or cytarabine plus
GTI-2040-loaded liposomes without anti-CD33 grafting.
Finally, several liposomal formulations using chemotherapeu-
tic drugs or antisense oligonucleotides are in various stages of
development (Table 2). Combination therapy with drug co-en-
capsulation or drug co-administration is now offered on a sys-yeloid leukemia, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.05.040
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TABLE 2
Examples of nanocarriers in current development to improve AML treatment
API class API Drug formulation Drug association Development stage Objectives Refs
Anthracyclin Daunorubicin Liposomes Yes (cytarabine) FDA approved and
clinical trial
investigations
Bypass drug resistance [55]
Yes (emetine) In vitro evaluation Modify
pharmacokinetics; target
AML cells
[64]
Doxorubicin Polymeric NPs No In vivo evaluation Modify
pharmacokinetics; target
AML cells; bypass drug
resistance
[77]
Polymeric micelles No In vitro evaluation Target AML cells [85]
Antipyrimidic Cytarabine Liposomes Yes (daunorubicin) FDA approved Bypass drug resistance [55]
Dendrimers No In vitro evaluation Modify
pharmacokinetics;
bypass drug resistance;
target AML cells
[88,89]
Iron NPs No In vitro evaluation [118]
Hypomethylating agent Decitabine Lipid NPs No Ex vivo, in vitro, and in
vitro evaluations
Modify administration
route (improve patients’
quality of life)
[112–114]
Protein kinase C inhibitors Safingol Liposomes No Reduce adverse effects;
modify
pharmacokinetics
[63]
Liposomes Yes (C2-ceramide) In vivo evaluation Reduce adverse effects [62]
C2-ceramide Liposomes Yes (Safingol) In vivo evaluation Reduce adverse effects [62]
Oligonucleotide antisense miR-126
antagonist
Liposomes No In vivo evaluation Target LSCs [49]
GTI-2040 Liposomes No In vivo evaluation Target AML cells [71]
CD44 siRNA Polymeric NPs No In vitro evaluation Target AML cells; modify
pharmacokinetics
[78,80]
siRNA Cyclodextrin-based NP No In vitro and ex vivo
evaluation
Target AML LSCs [48]
Differentiating agents All-trans retinoic
acid
NLCs No In vitro evaluation Modify administration
route
[103–105]
SLNs No In vitro evaluation;
physicochemical
characterization
Modify administration
route
[101,102]
Polymeric NPs No In vitro evaluation Modify administration
route
[76]
Topoisomerase II inhibitors Etoposide NLCs No In vitro evaluation Target cancerous cells;
modify current
formulation to reduce
adverse effects
[100]
Sphingosine 1-phosphate
receptor modulators
Fingolimod SLNs No In vivo evaluation Modify
pharmacokinetics; target
AML cells
[109]
Aurora B kinase inhibitors AZD2811 Polymeric NPs No In vivo evaluation Modify
pharmacokinetics
[74,75]
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IEWtematic basis. Liposomes have been designed to enhance drug
targeting and to overcome drug resistance, and their develop-
ment is continuing, with several formulations currently under
clinical evaluation.
Nanoparticles based on polymers
Those particles in the nano-size range contain supramolecular
associations of polymers (micelles and dendrimers) and aggregated
dense polymeric particles. The stability of these formulations in
the body can be very different, as can their toxicity and scale-up
ability. Thus, the future of these formulations in the clinic is linked
not only to their performance, but also to their fate in the humanPlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute m
8 www.drugdiscoverytoday.combody, resulting from their physicochemical properties. The diffi-
culties in producing and accurately characterizing large-scale
batches could hinder their future development.
Polymeric NPs
Polymeric NPs (Fig. 1) are NPs formulated from polymers and
designed to encapsulate hydrophilic or lipophilic drugs depending
on the formulation process used. Along with liposomes, polymeric
NPs represent the most significant nanomedicine categories ap-
proved by the FDA [73].
For AML indications, one clinical trial using polymeric NPs has
been registered (Table 1), and others are currently being investi-
gated in preclinical models.yeloid leukemia, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.05.040
Drug Discovery Today Volume 00, Number 00  June 2018 REVIEWS
DRUDIS-2262; No of Pages 14
Re
vi
ew
s
 K
EY
N
O
TE
R
EV
IE
WPolymeric NPs encapsulating AZD2811, a molecularly targeted
agent (aurora B kinase inhibitor), have been developed and will be
evaluated in an approved clinical trial (NCT03217838). NPs com-
prise block copolymers of poly-D,L-lactic acid (PLA) and PEG. A
nanoemulsion of benzyl alcohol and an aqueous phase containing
an organic acid have previously been obtained. The organic acid
led to a counterion interaction with AZD2811, increasing drug
encapsulation efficiency and decreasing the release rate of the drug
[74]. An in vivo pharmacokinetic study using a rat-based model
confirmed the slow release of the drug, extending its exposure
profile. Pharmacodynamic studies in multiple preclinical models
have demonstrated that AZD2811-loaded NPs were more effective
in inhibiting tumor growth when administered at half of the dose
of AZD1152. AZD1152 corresponds to the AZD2811 phosphory-
lated prodrug (also known as barasertib) [74]. In a HL-60-xeno-
grafted mouse-based model, AZD2811 NPs showed the potential to
improve AZD2811 efficacy in regressing tumor size at the various
doses investigated, as well as being well tolerated [75]. When
combined with cytarabine in the same model, tumor size regres-
sion and the sustainability of the response were increased com-
pared with cytarabine alone or AZD2811 NPs alone. When
AZD1152 (used at a higher total dose compared with AZD2811
NPs) was combined with cytarabine, the duration of the response
was reduced, confirming the potential of AZD2811-PLA NPs [75].
Simon et al. developed NPs to encapsulate ATRA in polymeric
NPs based on poly-D,L-lactide-co-glycolide (PLGA) polymer [76].
PLGA NPs were obtained using the solvent evaporation technique.
After a lyophilization process, the mean particle size was 150–
200 nm. The NPs did not affect the antiproliferative and differen-
tiation capabilities of ATRA in HL-60 cells when entrapped. Given
that PLGA NPs are already used for parenteral administration, and
PLGA is a FDA-approved polymer for parenteral use, the authors
concluded that ATRA polymeric NPs could be useful for intrave-
nous administration, particularly because the release of the drug
was prolonged. Currently, ATRA is only available for oral admin-
istration, and a parenteral administration method could be re-
quired for patients who are unable to swallow.
Multifunctional lipid-polymeric NPs loaded with doxorubicin
and obtained by the nanoprecipitation method have also been
developed [77]. In this strategy, doxorubicin was encapsulated in a
polymeric core comprising PLGA and Pluronic1 85 (co-polymers
based on ethylene oxide and propylene oxide). Transferrin was
then grafted onto a lipidic shell comprising stearic acid, after being
conjugated to PEG and oxalic acid. The grafting led to the targeting
of transferrin receptors expressed in leukemic cells. Particles had a
mean size of 160 nm and a negative charge. The formulation
showed the ability to prolong doxorubicin plasma circulation
time in a rat-based model. The mean residence time was enhanced
by a factor of at least five. Tumor reduction volume in a mouse-
based model xenografted with HL-60 cells or doxorubicin-resistant
HL-60 cells was also enhanced. Doxorubicin multidrug resistance
was also overcome, probably because of the presence of Pluronic1
85 in the core of the NPs, which is able to inhibit p-glycoprotein.
A specific CD44 siRNA to target LSCs loaded in polymeric NPs
has also been developed [78]. CD44, an adhesion molecule, is
associated with poor AML prognosis and high level of AML relapse
[79]. Lipid-modified polyethyleneimine dissolved in water was
added to CD44-specific siRNA, solubilized in a saline mediumPlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute m[80]. The mean size of the complexes obtained was <100 nm
[80]. Gul-Uludag et al. loaded specific CD44 siRNA into these
polymeric NPs in a 8:1 polymer:siRNA weight ratio [78]. They
investigated the silencing efficiency of CD44 in a AML cell line
model known to express a high level of CD44 (KG-1 cells). After 3
days, CD44 silencing was significantly superior when CD44 siRNA-
loaded polymeric NPs were applied compared with scramble
siRNA-loaded polymeric NPs. The cytotoxic activity of CD44
siRNA-loaded polymeric Nps was also more important than the
cytotoxicity of the polymer–SCR–siRNA complexes. Experiments
were only performed in in vitro models, and need to be continued
to confirm the potential of this polymeric formulation compared
with the toxicity of CD44-neutralizing antibodies previously
reported in clinical trials [81].
Micelles
Polymeric micelles are largely used in cancer therapies involving
lipophilic drugs [82]. Their pharmacokinetic behavior is driven by
the hydrophilic structure of their shell [83]. Polymeric micelles
were recently approved by different medicines agencies and are
good candidates for solubilizing hydrophobic drugs (notably pac-
litaxel) without the need for a toxic surfactant. Polymeric micelle
formulations of paclitaxel already exist and are used in the clinic
(e.g., Genexol-PM1, Samyang-Biopham; Nanoxel-M1, Samyang-
Biopham; and Paclical1, Oasmia Pharmaceutical AB) [84].
Doxorubicin-loaded polymeric micelles have been developed
for AML indications [85]. Dextran was used as a copolymer, and
folic acid and retinoic acid were then grafted onto the shell of the
micelles to target AML cells. The micelles had a mean size of 80–
100 nm and a encapsulation efficiency of at least 90%. The in vitro
cytotoxic activity of doxorubicin-loaded polymeric micelles
grafted with folic acid was enhanced in KG-1 cells compared with
the free drug. The concentration required to provide 50% cell
death was approximately twice as high using doxorubicin alone
compared with doxorubicin-loaded polymeric micelles grafted
with folic acid. When folic acid was not grafted, no difference
between the free drug and drug-loaded micelles was observed,
demonstrating the importance of the folic acid ligand.
More advanced assessments are required to consider micelles for
clinical trials in AML treatments.
Dendrimers
Dendrimers are 3D branched structures with a nano-size range
(Fig. 1). They are useful for improving the solubility of hydropho-
bic drugs. Moreover, a range of terminal functional groups exists
and, thus, dendrimers are ideal for drug delivery systems and
targeting strategies [86]. Drugs can be conjugated or encapsulated
into the core of the dendrimer. In cancer therapy, dendrimers have
been used to control drug release and specific drug targeting [87].
No dendrimer particles are currently involved in any clinical
trial for AML treatment. However, the literature includes several
studies assessing their potential to improve treatment.
Dendrimers for cytarabine encapsulation have been developed
by Szulc et al. [88]. First, maltose residues were attached at the
amino terminal group of poly(propylene imine). Cytarabine tri-
phosphate was then mixed with dendrimer in phosphate buffer
saline, and a complex was finally obtained as a result of ionic
interactions between the negatively charged cytarabine and the
cationic dendrimer [89]. Cytarabine triphosphate-complexed den-
drimers did not significantly decrease HL-60 cell viability com-yeloid leukemia, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.05.040
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phosphate-complexed dendrimers significantly increased the cy-
totoxic potency of cytarabine on the 1301 cell line (a T cell
leukemia cell line). According to the authors, this enhancement
resulted from an additional entry or toxicity mechanism [88].
There are no dendrimer-bound chemotherapy formulations
currently on the market. For AML indications, few in vitro studies
are underway, and these need to be developed through in vivo
studies. These formulations also need to be scaled up before
clinical applications can be considered.
Lipid-based nanoparticles
There is a range of lipophilic drugs available but they cannot be
solubilized in aqueous media in great quantity. Liposomes, as
mentioned above, were originally designed for hydrophilic drugs.
Lipophilic drugs can be encapsulated into liposomes as previously
described and are then located in the phospholipid bilayer or
grafted onto the surface. In the latter case, rapid release of the
drug can be observed, and the drug loading is limited. Lipid NPs
can be used to prevent this burst release and to enhance drug
loading in NPs.
Two main kinds of lipid-based NP are currently being devel-
oped; solid lipid NPs (SLNs), with a solid lipid matrix, and nano-
structured lipid carriers (NLCs), comprising solid lipids and liquid
lipids (Fig. 1). In the ideal scenario, lipid-based NPs can be prepared
using a low energy process, do not require the use of organic
solvent, and can be scaled up [90–92]. Thus, numerous lipophilic
cytotoxic drugs have been encapsulated in lipid-based NPs, such as
paclitaxel, etoposide, docetaxel, SN38, and doxorubicin; some
drugs have been modified to be more lipophilic, such as carbon-
yl-grafted gemcitabine [93–97]. However, there are currently no
lipid-based NPs either on the market or undergoing clinical trials.
Etoposide has been found to be active in de novo relapsed AML
[98], and can be used in combination with cytarabine in patients
who are either older with AML or have refractory AML [99]. Given
its poor water solubility, etoposide in its commercial formulation
is only available combined with alcohol and surfactants, such as
polysorbate 80 or Cremophor EL, which display cell toxicities.
Therefore, etoposide lipid-based nanocarrier formulations were
developed for AML indications. Khajavinia et al. developed etopo-
side-loaded lipid nanocarriers conjugated with transferrin [100].
Particles were prepared by an emulsion–solvent diffusion and
evaporation method followed by sonication. The lipid phase,
containing etoposide, was dissolved in a mixture of acetone and
ethanol, and comprised cetylpalmitate, octyldodecanol, soy
lecithin, and a fatty amine. A solution of poloxamer 188 was
mixed and the emulsion was then ultrasonicated. Finally, trans-
ferrin was conjugated to lipid nanocarriers. The size of particles
ranged from 158 nm to 247 nm, depending on the fatty amine and
the transferrin conjugation method used. When etoposide was
loaded into lipid nanocarriers, its cytotoxic activity on K562 cells
was systematically enhanced compared with free etoposide.
Given its lipophilic structure, ATRA is a good candidate for lipid-
based NPs, and there are numerous examples in the literature of
lipid-based NPs for ATRA encapsulation. One example is ATRA-
loaded SLNs obtained by an emulsification-ultrasound process
[101,102]. Depending on the components and the oil:surfactant
ratio of the SLNs, particles ranged in size from 75 nm to >200 nmPlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute m
10 www.drugdiscoverytoday.com[101,102]. In vitro cytotoxicity assessments have been carried out
on different acute leukemia cell lines (HL-60, Jurkat, and THP-1)
[101]. On the HL-60 cell line, ATRA-loaded SLNs significantly
decreased cell viability compared with ATRA in solution. On
the Jurkat and THP-1 cell lines, ATRA was inactive, even at high
doses. When ATRA was loaded in SLNs, a significant, but modest,
decrease in cell viability was observed. Several ATRA-loaded NLCs
have also been developed to increase drug loading compared with
SLNs. Sabzichi et al. used a high-pressure homogenization tech-
nique to produce ATRA-loaded NLCs [103]. A mixture of solid and
liquid lipids was produced, followed by the addition of a surfactant
(poloxamer 407) under high pressure homogenization. A hot oil-
in-water emulsion was produced before it was cooled down to
ambient temperature, resulting in particles from 65–115 nm.
Chinsriwongkul et al. and Ourique et al. developed NLCs for ATRA
encapsulation using an homogenization technique [104,105].
Particles of 200 nm with a narrow PDI and negative zeta potential
were obtained, and the cytotoxicity of the ATRA was increased
compared with free solution in HL-60 cells. The concentration
required to achieve 50% cell growth inhibition for ATRA-loaded
LNCs was half or less (depending on the oil used to produce the
NLCs) that required for an ATRA solution. [104]. Ourique et al.
developed NLCs of 213 nm with an increased lipid-core viscosity
to retain ATRA and to reduce ATRA leakage from NLCs. ATRA was
dispersed in the lipid core, comprising sorbitan monostearate and
a caprylic/capric triglyceride mixture, and demonstrated a similar
antiproliferative effect on an AML cell line (HL-60) to that of the
free drug [105].
As previously discussed, new targets are being investigated, for
example, protein phosphatase 2A (PP2A), which is functionally
inactivated in numerous cancers and leukemias [106,107]. Phar-
macological restoration of PP2A antagonizes cancer development
and progression. Fingolimod, a sphingosine analog (also known as
FTY720) is one molecule able to activate PP2A [106]. It is a water-
soluble drug with a high oral bioavailability and is FDA approved
for patients with multiple sclerosis. Fingolimod has also been
evaluated for AML treatment and, according to a systemic evalua-
tion of its safety and toxicity, it appears to be a potential treatment
option for AML, because of an acceptable benefit:risk ratio and a
lack of bone marrow toxicity [108]. Fingolimod has also been
encapsulated in SLNs prepared by hot homogenization followed
by sheer homogenization and ultrasonication [109]. NPs of
207 nm were obtained. Cytotoxic activity in AML cells (HL-60),
pharmacokinetics following oral administration (in a mice-based
model), and antitumor activity of fingolimod-loaded NPs were
evaluated and compared with a fingolimod solution. Fingolimod-
loaded SLNs induced a higher percentage of apoptosis. Moreover,
oral bioavailability was enhanced by a factor of nine (the maxi-
mum drug concentration was enhanced by a factor of 40), and
significantly decreased tumor burden in a HL-60 xenografted
mouse-based model.
Therefore, NPs could be developed to increase the oral bioavail-
ability of drugs, allowing oral administration of drugs only avail-
able by intravenous infusion because of their physicochemical
structures. Such strategies have been proposed for hypomethylat-
ing agents, such as AZA or DEC, which are only available by
subcutaneous or intravenous infusion, respectively. Oral formula-
tions might be more convenient for patients, eliminate injectionyeloid leukemia, Drug Discov Today (2018), https://doi.org/10.1016/j.drudis.2018.05.040
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tion [110]. Oral AZA (CC-486) has been assessed in a Phase 1 trial
[111] for AML and MDS, and a Phase 3 trial in low-risk MDS is
ongoing (NCT01566695), showing the interest in the possible oral
administration of such agents. DEC encapsulation in lipid-based
NPs for oral administration is currently under investigation [112–
114]. For example, after DEC solubilization in Transcutol1HP and
Precirol1 ATO5, followed by homogenization under high pressure
(500–1000 bar) in cold conditions, particles of 116 nm were
obtained by Neupane et al. [113]. An ex vivo permeation study
(on an ileum segment) was performed and a fourfold increase in
DEC in vitro permeability was observed compared with a DEC
solution [112]. When DEC was loaded into an NLC formulation
of 30 nm obtained using a low-energy phase inversion process, its
cytotoxicity on two AML cell lines (HEL and HL-60) was enhanced
by a factor of 1.5 on HEL cells and 1.8 on HL-60 cells compared
with free DEC [114]. Moreover, the apparent permeability of an
NCL formulation across a Caco-2 cells monolayer was enhanced by
a factor of over nine. The major issue for the clinical development
of oral nucleotide analogs is their rapid clearance in the gut and
liver by cytidine deaminase. A dose escalation trial of concomitant
oral administration of DEC and a cytidine deaminase inhibitor
(E7727) has been conducted, with promising results [115].
Lipid-based NPs are currently undergoing in vitro or in vivo
assessments with regard to AML treatment. Promising strategies
have been suggested to enhance drug targeting, to modify phar-
macokinetics of drugs already used in AML treatment, or to modify
the administration route to facilitate drug administration or to
improve patients’ quality of life. New therapeutic strategies, such
as fingolimod used for AML indications, are also being developed.
As a result of strategies developed to enhance drug loading, and
after quality control improvements in the field of lipid NPs, such
strategies can be tested in clinical trials.
Metallic nanoparticles
Metallic NPs have mostly been developed as part of theranostic
strategies, because of a combination of superparamagnetic prop-
erties and reactive oxygen species production capabilities used to
destroy cancer cells. They can be used as drug carriers because of a
covalent conjugation with drugs or imaging agents. Chemothera-
peutic drugs generally attached to iron NPs are characterized by
low molecular weights, rapid biodistribution, and rapid clearance.
Once attached to iron NPs, blood circulation time is increased as
well as EPR effects, enhancing tumor retention [116,117]. Metallic
NPs include iron, gold, silver, zinc, and titanium, and can be
produced on a large scale, although they have to demonstrate
their good tolerance and the lack of body accumulation over time
if chronic administration is to be realized.
No metallic NP formulation is currently under clinical investi-
gation for AML indications. A strategy designed to conjugate
cytarabine with iron NPs coated with silica has been presentedPlease cite this article in press as: Briot, T. et al. Advances in treatment formulations for acute m[118]. Mean particle size varied from 23 nm to 57 nm depending
on the method used to measure it (microscopy or dynamic light
scattering). The cytotoxic capacity of these negatively charged
particles (11.5 mV) was evaluated in AML cell lines (HL-60
and KG-1). An improvement of the antiproliferative effect of
cytarabine was observed when it was conjugated with iron NPs.
The concentration of NPs required to achieve 50% cell growth
inhibition was half of that required for free cytarabine.
Iron NPs are preferred for their superparamagnetic properties
and imaging capability. Using such NPs to conjugate chemothera-
pies could prove a promising approach for combining treatment
and diagnostics. However, there is currently little work assessing
this strategy for AML indications.
Concluding remarks
Here, we have discussed current treatments and innovative for-
mulations (Table 1) that have either been recently approved or are
in different stages of development (clinical trials, in vivo or in vitro
evaluations) for use against AML. These new formulations are
designed to overcome drug resistance or to bypass adverse effects
of APIs currently used in chemotherapy (Fig. 1). As is the case in
other pathologies where NPs are developing, liposomes remain the
most advanced area, with ongoing clinical trials and a recent FDA-
approved formulation (Vyxeos1). The second NP category for
which future trial investigations are planned is polymeric NPs.
Clinical transfer from laboratory investigations using other NP
strategies must address inadequate drug loading, toxicity evalua-
tions, and scaling-up issues. As previously reported, the transfer
from bench to bedside is a major challenge for nanomedicines
[119,120].
Finally, four main research approaches are developing in AML
formulation research, namely AML cell line targeting, overcoming
drug resistance, modifying the pharmacokinetics of drugs, and
modifying administration routes for clinical reasons. If pathology
outcomes cannot be modified in the near term for refractory AML,
NPs could help to improve patients’ quality of life by minimizing
pain, inconvenience caused by the administration route, or the
adverse effects of treatment. Over the longer term, there is a
requirement to ensure the best possible AML outcomes, and
combining innovative formulations and new targets recently dis-
covered could contribute to significant improvements. Innovative
formulations open the field of personalized therapy in combina-
tion with newly identified biomarkers.
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